Pacira BioSciences (PCRX) SVP Lauren Riker Sells $144K of Stock
Senior VP Lauren Riker sold 6,115 shares of PCRX on June 11, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Lauren Riker, Senior Vice President, Finance at Pacira BioSciences, Inc. ($PCRX), sold 6,115 shares at an average price of $23.50, worth about $143,702.50, on June 11, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $PCRX is down 4.4% after 1 week, up 9.3% after 1 month and up 55.6% to date (from the $23.36 close on Jun 11, 2026).
PCRX
Pacira BioSciences, Inc.
Key Points
- Lauren Riker, Senior Vice President of Finance at PCRX, sold 6,115 shares on June 11, 2026, for a total of $143,702.50.
- PCRX shares recently traded at $22.99, with analysts maintaining varied ratings and price targets ranging from $24 to $38.
- Other funds like BlackRock and Vanguard have adjusted their positions in PCRX, with BlackRock reducing and Vanguard increasing their holdings.
Get $PCRX trade alerts by text
We text you when insiders, Congress or big funds trade $PCRX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Pacira BioSciences, Inc. alert may contain errors. Disclosures
Lauren Riker, who serves as the Senior Vice President of Finance at PCRX, recently sold 6,115 shares of the company. The transaction took place on June 11, 2026, at an average price of $23.50 per share, amounting to a total value of $143,702.50. This planned sale was executed under a pre-arranged trading plan.
Other Institutional Activity in PCRX
Several institutional investors have also adjusted their holdings in PCRX. BlackRock, Inc. reduced its position by 328,937 shares, ending with 6,735,343 shares valued at approximately $152.2 million. Vanguard Portfolio Management LLC increased its stake significantly by adding 2,501,286 shares, bringing its total to 2,501,286 shares worth about $56.5 million. Meanwhile, Dimensional Fund Advisors LP boosted its holdings by 110,584 shares, resulting in a total of 2,060,597 shares valued at roughly $46.6 million.
Pacira BioSciences, Inc. Stock Down 6.9%
Shares of PCRX recently traded at $22.99. The company has seen some movement in its stock, with analysts maintaining various ratings. The stock has been the subject of recent analyst reports, with price targets ranging from $24 to $38.
Insider Buying and Selling at Pacira BioSciences, Inc.
In addition to Lauren Riker's sale, other insiders have been active in PCRX. On June 10, 2026, Michael Yang acquired 6,405 shares, and Christopher Christie also bought 6,405 shares. Laura Brege purchased 10,891 shares and an additional 6,405 shares on the same day. These transactions were not part of a pre-planned trading strategy.
Analysts Set New Price Targets
On May 1, 2026, RBC Capital maintained a 'hold' rating on PCRX with a $24 target. Needham also maintained its 'buy' rating with a $32 target. Barclays, on March 26, 2026, reiterated a 'hold' rating with a price target of $25. Analysts have a consensus recommendation of 'buy', with an average target price indicating potential upside.
Bottom Line
Lauren Riker's planned sale of PCRX shares highlights ongoing insider activity at the company. Investors often track such transactions for potential insights into company prospects. It's important to remember that these trades are disclosed after they occur and may not reflect current insider sentiment. As always, these filings are historical and provide a snapshot of past activity.
Related Filing Alerts
Source: Lauren Riker's Form 4 filing on $PCRX (Jun 11, 2026). Find the original filing: PCRX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts